Sign In
Buy ALLR
$1.19
-0.0300 (-2.46%)
At Close: Jul 24, 2026
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Comp
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect
10:00am, Sunday, 12'th Jan 2025
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Comp
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Compa
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Compa
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Compa
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Com
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
08:00am, Monday, 18'th Nov 2024
Boston (November 18, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized canc
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
02:41pm, Tuesday, 12'th Nov 2024
LOS ANGELES--(BUSINESS WIRE)--ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) and c
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:00am, Tuesday, 12'th Nov 2024
LOS ANGELES , Nov. 12, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Al
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity The
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
03:45pm, Monday, 11'th Nov 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options NEW YOR
LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity The
